title: The differences in CXCR4 protein expression are significant for the five molecular subtypes of breast cancer.
abstract: The aim was to investigate the expression of the CXCR4 protein in five molecular subtypes of breast cancer. The authors randomly selected the breast cancer paraffin-embedded specimens of the Affiliated Third Hospital of Harbin Medical University between 2007 and 2009. Details are as follows: basal-like subtype-ER (-), PR (-), C-erbB-2 (-), CK5/6 (+), n = 36; normal breast subtype-ER (-), PR (-), C-erbB-2 (-), CK5/6(-), n = 40; luminal A subtype-ER/PR (+), C-erbB-2 (-), n = 38; luminal B subtype-ER/PR (+), C-erbB-2 (+), n = 60; C-erbB-2 (+) subtype-ER (-), PR (-), C-erbB-2 (+), n = 58. Using the immunohistochemistry method, the authors detected the expression of the CXCR4 protein in the five subtypes. The CXCR4 protein expression in the basal-like subtype was the highest, and that in the luminal A subtype was the lowest. In terms of five molecular subtypes of breast cancer, the differences in CXCR4 protein expression were significant (p < .001). In terms of C-erbB-2 expression, tumor stage, and lymph node metastasis of breast cancer, the differences in CXCR4 protein expression were significant (p < .01).
authors.affiliation: Department of Breast Surgery, Affiliated Third Hospital of Harbin Medical University, Harbin, China.
authors.forename: Ming
authors.initials: M
authors.lastname: Zhang
authors.forename: Hai-Xia
authors.initials: HX
authors.lastname: Liu
authors.forename: Xiao-Dan
authors.initials: XD
authors.lastname: Teng
authors.forename: Hong-Bin
authors.initials: HB
authors.lastname: Wang
authors.forename: Jing
authors.initials: J
authors.lastname: Cui
authors.forename: Shu-Sheng
authors.initials: SS
authors.lastname: Jia
authors.forename: Xin-Yue
authors.initials: XY
authors.lastname: Gu
authors.forename: Zhi-Gao
authors.initials: ZG
authors.lastname: Li
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry* / Q000145:classification / Q000473:pathology; D016009:Chi-Square Distribution; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053555:Keratin-5 / Q000032:analysis; D053553:Keratin-6 / Q000032:analysis; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D019718:Receptors, CXCR4 / Q000032:analysis*; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis
chemical_list: D014408:Biomarkers, Tumor; D053555:Keratin-5; D053553:Keratin-6; D018719:Erb-b2 Receptor Tyrosine Kinases; D019718:Receptors, CXCR4; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C527276:CXCR4 protein, human; C503940:KRT5 protein, human; C508053:ERBB2 protein, human